Encouragingly, a recent Phase Ib study demonstrated a promising early efficacy of PD-L1 inhibitor atezolizumab combined with anti-angiogenic agent bevacizumab in systemic treatment-naïve, advanced HCC with an ORR of 62%.[75] Indeed, the superiority of this combination over sorafenib in the first line setting has now been demonstrated in a confirmatory phase 3 study.[28]. Here, CD274 is linked to hepatocellular carcinoma.